CN114522223A - 一种纠正皮肤褶皱的注射液及其生产工艺 - Google Patents
一种纠正皮肤褶皱的注射液及其生产工艺 Download PDFInfo
- Publication number
- CN114522223A CN114522223A CN202210296734.3A CN202210296734A CN114522223A CN 114522223 A CN114522223 A CN 114522223A CN 202210296734 A CN202210296734 A CN 202210296734A CN 114522223 A CN114522223 A CN 114522223A
- Authority
- CN
- China
- Prior art keywords
- injection
- vitamin
- solution
- amino acid
- antioxidant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002347 injection Methods 0.000 title claims abstract description 71
- 239000007924 injection Substances 0.000 title claims abstract description 71
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 26
- 230000037303 wrinkles Effects 0.000 title claims abstract description 22
- 102000008186 Collagen Human genes 0.000 claims abstract description 46
- 108010035532 Collagen Proteins 0.000 claims abstract description 46
- 229920001436 collagen Polymers 0.000 claims abstract description 46
- 239000000243 solution Substances 0.000 claims abstract description 41
- 229930003231 vitamin Natural products 0.000 claims abstract description 40
- 235000013343 vitamin Nutrition 0.000 claims abstract description 40
- 239000011782 vitamin Substances 0.000 claims abstract description 40
- 229940088594 vitamin Drugs 0.000 claims abstract description 40
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 37
- 150000001413 amino acids Chemical class 0.000 claims abstract description 28
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 22
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 22
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 20
- 239000003589 local anesthetic agent Substances 0.000 claims abstract description 19
- 239000004005 microsphere Substances 0.000 claims abstract description 14
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 26
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 26
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical group [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 26
- 229940024606 amino acid Drugs 0.000 claims description 25
- 235000001014 amino acid Nutrition 0.000 claims description 25
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 235000006708 antioxidants Nutrition 0.000 claims description 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 13
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 13
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 13
- 229940087603 grape seed extract Drugs 0.000 claims description 13
- 235000002532 grape seed extract Nutrition 0.000 claims description 13
- 239000001717 vitis vinifera seed extract Substances 0.000 claims description 13
- 239000001814 pectin Substances 0.000 claims description 12
- 229920001277 pectin Polymers 0.000 claims description 12
- 229960004393 lidocaine hydrochloride Drugs 0.000 claims description 11
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 claims description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- 239000004471 Glycine Substances 0.000 claims description 9
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 9
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 9
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 9
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 9
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 9
- 235000004279 alanine Nutrition 0.000 claims description 9
- 229960000310 isoleucine Drugs 0.000 claims description 9
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 9
- 239000008215 water for injection Substances 0.000 claims description 9
- 108010024636 Glutathione Proteins 0.000 claims description 8
- 229960003180 glutathione Drugs 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 7
- 229930003268 Vitamin C Natural products 0.000 claims description 7
- 239000007853 buffer solution Substances 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 235000019154 vitamin C Nutrition 0.000 claims description 7
- 239000011718 vitamin C Substances 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 229930003270 Vitamin B Natural products 0.000 claims description 6
- 235000019156 vitamin B Nutrition 0.000 claims description 6
- 239000011720 vitamin B Substances 0.000 claims description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 5
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 235000010987 pectin Nutrition 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 235000019155 vitamin A Nutrition 0.000 claims description 5
- 239000011719 vitamin A Substances 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- 229940045997 vitamin a Drugs 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 108010087806 Carnosine Proteins 0.000 claims description 4
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 230000002572 peristaltic effect Effects 0.000 claims description 4
- 239000002504 physiological saline solution Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 229930182555 Penicillin Natural products 0.000 claims description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 3
- 239000003708 ampul Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 229940049954 penicillin Drugs 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 229960002372 tetracaine Drugs 0.000 claims description 3
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims description 3
- YBHYYFYQHRADCQ-UHFFFAOYSA-N 2-aminoacetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound NCC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O YBHYYFYQHRADCQ-UHFFFAOYSA-N 0.000 claims description 2
- 238000009924 canning Methods 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 230000003444 anaesthetic effect Effects 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 15
- 239000000047 product Substances 0.000 abstract description 8
- 238000005516 engineering process Methods 0.000 abstract description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 210000002744 extracellular matrix Anatomy 0.000 abstract description 4
- 230000032683 aging Effects 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 238000001338 self-assembly Methods 0.000 abstract description 3
- 239000013589 supplement Substances 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 230000000857 drug effect Effects 0.000 abstract description 2
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 43
- 230000000052 comparative effect Effects 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000001502 supplementing effect Effects 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960005188 collagen Drugs 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002077 nanosphere Substances 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- -1 and more preferably Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种纠正皮肤褶皱的注射液及其生产工艺,它是以高分子粘多糖,氨基酸,重组人源胶原蛋白,维生素,局部麻药,抗氧化剂为主要成分的复方溶液,包括:高分子粘多糖2~8g/L;氨基酸400~800mg/L;重组人源胶原蛋白50~500mg/L;维生素1~20mg/L;局部麻药0.2~0.8mg/L;抗氧化剂0.5~2g/L;PRP凝胶1~20mg/L。高分子粘多糖、胶原蛋白配合PRP凝胶可有效补充胞外基质和胶原蛋白,氨基酸和维生素可促进人体自身胶原蛋白的合成,抗氧化剂提供皮肤抗氧化衰老的作用,各成分协同作用保证了该注射液具有可快速纠正皮肤褶皱,并持续改善肤质的功效,同时局部麻药减轻了注射初期的不适。该产品在生产工艺上采用了自组装纳米微球技术,提高了用药稳定性,保证了药效。
Description
技术领域
本发明涉及一种纠正皮肤褶皱的注射液及其生产工艺,它是以高分子粘多糖,氨基酸,胶原蛋白,维生素,局部麻药,抗氧化剂,PRP凝胶和注射用水为主要成分的复方溶液。该产品具有可快速纠正皮肤褶皱,并持续改善肤质的功效。本发明为植入内医疗器械、皮肤营养等领域。
背景技术
皮肤褶皱是年龄增长过程中不可避免的问题,主要原因是细胞衰老等内因和紫外线等外因共同导致的胞外基质、胶原蛋白流失。目前市面上的皮肤营养品也多以补充这两种物质为主,但大多数产品都存在药效单一、见效慢、副作用多、持续性不强等缺点。
透明质酸和硫酸软骨素都是皮肤胞外基质中的重要物质,前者具有极强的锁水性,后者可促进纤维细胞增殖,这些功能保证了皮肤紧致、水润有弹性。然而随着衰老,透明质酸和硫酸软骨素都会减少,导致皮肤褶皱、松弛。
皮肤中有70%的成分都是胶原蛋白,其是维持皮肤与肌肉的弹性的主要成分。随着年龄增长,胶原蛋白会不断流失,直接补充胶原蛋白虽然见效快,但不完全安全,并需要长期注入,增加了患者的痛苦,所以促进人体合成自身胶原蛋白是最理想的治疗方式。氨基酸是合成胶原蛋白的原料,维生素是合成胶原蛋白过程中重要的辅助因子,运用自组装纳米微球技术,将氨基酸包封于载体内,能显著提高稳定性,并且在较长的时间内持续释放氨基酸。
局部麻药是常见的注射液添加物,美容注射初期难免存在排异反应或其他症状,补入少量局部麻药可减少患者的不适感。
抗氧化剂能够有效抑制自由基对透明质酸钠的降解,并且增强皮肤抵抗光老化的能力,大多美容产品都会添加抗氧化剂,其种类繁多,例如超氧化物歧化酶、谷胱甘肽还原酶、L-肌肽、维生素A,维生素E等等。
PRP是含有高浓度血小板的自体血浆,其包含众多生长因子,对于细胞分化增殖,以及胞外基质、胶原蛋白的生成至关重要。
发明内容
本发明的目的是提供一种纠正皮肤褶皱的注射液及其生产工艺,该注射液以高分子粘多糖,氨基酸,胶原蛋白,维生素,抗氧化剂,PRP凝胶和注射用水为主要成分,能够快速纠正皮肤褶皱,并持续改善肤质,同时添加了局部麻药减轻了患者注射初期的不适。在生产工艺上,该产品采用了自组装纳米微球技术,保证了功效组分稳定到达患处,提高了用药稳定性。该注射液安全稳定,疗效明显,无毒副作用,适用于纠正人体各处皮肤褶皱。
本发明的上述技术目的是通过以下技术方案得以实现的:
本发明提供一种纠正皮肤褶皱的注射液,其特征在于它的质量组成:高分子粘多糖2~8g/L;氨基酸400~800mg/L;重组人源胶原蛋白50~500mg/L;维生素1~20mg/L;局部麻药0.2~0.8mg/L;抗氧化剂0.5~2g/L;PRP凝胶1~20mg/L。
优选的,所述的高分子粘多糖为透明质酸钠和硫酸软骨素,质量比为8:2,其中透明质酸钠交联与非交联形式的质量比为7:3。
优选的,所述氨基酸包括脯氨酸,甘氨酸,丙氨酸,亮氨酸,异亮氨酸,质量比为3:3:3:0.5:0.5。
优选的,所述维生素包括维生素A,维生素B,维生素C和维生素E,质量比为1:4:4:1。
优选的,所述局部麻药为盐酸利多卡因或丁卡因,更为优选的,所述局部麻药为盐酸利多卡因。
优选的,所述抗氧化剂为葡萄籽提取物,L-肌肽,谷胱甘肽中的一种或多种,更为优选的,所述抗氧化剂为葡萄籽提取物和谷胱甘肽混合物,质量比为1:4。
可选的,本发明提供的纠正皮肤褶皱的注射液特征在于它的质量组成:高分子粘多糖6~8g/L;氨基酸400~800mg/L;重组人源胶原蛋白50~500mg/L;维生素1~20mg/L;局部麻药0.2~0.8mg/L;抗氧化剂1.8~2g/L;PRP凝胶1~20mg/L。进一步的,所述高分子粘多糖为透明质酸钠,其交联与非交联形式的质量比为2:8。
可选的,本发明提供的纠正皮肤褶皱的注射液特征在于它的质量组成:高分子粘多糖6g/L;氨基酸700mg/L;重组人源胶原蛋白400mg/L;维生素12mg/L;局部麻药0.5mg/L;抗氧化剂1.5g/L;PRP凝胶10mg/L。
本发明还提供一种用于纠正皮肤褶皱的注射液的生产工艺,其特征在于包括以下步骤:
S1,PRP凝胶制备:
S11,取新鲜静脉血液,加入ACD-A,低温(1~3℃)冷冻离心10~15min(离心力150×g),保留上层血浆,再将血浆离心25min(离心力250×g),保留下层血小板和少量血浆,振荡混匀,得到A液;
S12,取氯化钙经纳米分散机处理后,加入A液,置于36~37℃恒温水浴条件下反应24h,得到PRP凝胶;
S2,注射液制备
S21,36~37℃恒温水浴的条件下,将重组人源胶原蛋白溶解于生理盐水中,加入PRP凝胶,充分混合后加入注射用水,充分搅拌,得到a液;
S22,55~60℃恒温水浴的条件下,将高分子粘多糖、抗氧化剂、局部麻药和维生素按比例溶于注射水,混合均匀,冷却至36.5℃,得到溶液b;
S23,将酯化果胶溶于常温缓冲溶液中,加入氨基酸溶液,30~35℃恒温水浴反应2~4h,再回流反应1~2h,用透析袋透析后真空干燥袋内物质,得到氨基酸-果胶纳米微球,袋外溶液全部留存,记为c液;
S24,在36~37℃恒温条件下,将a液、b液和c液充分混匀,采用低功率均质机进一步处理,静置24~28h,得到d液;
S25,将氨基酸-果胶纳米微球加入d液,充分混合后通过0.5mol/L的盐酸调整pH至7.0~7.2,完成后用蠕动泵罐装至西林瓶或者安瓿瓶中,进行高压蒸汽灭菌,得到产品。
优选的,所述的注射液生产工艺,其特征在于所述缓冲溶液为甘氨酸-柠檬酸缓冲溶液,pH=4.5;所述酯化果胶De=70%;所述纳米微球粒径为50~200nm。
本发明提供的注射液生产工艺中,PRP凝胶制备环节通过低温冷冻离心,提高了分离效率,增加血小板浓度;在36~37℃条件下以超细氯化钙作为激活剂,能够加速凝胶中形成三维立体网状结构的纤维蛋白,有利于生长因子附着,该PRP凝胶注射入人体后还具有缓释效果。注射液生产全程,都为PRP凝胶提供了36~37℃的适宜孵化温度,其中的纤维蛋白可进一步丰富,提高生长因子浓度。生产工艺中,将制备氨基酸-果胶纳米微球的透析液收集后补加到后续环节,既保证了成品中氨基酸的含量,同时提供了游离的氨基酸,利于前期自身胶原蛋白的迅速合成,并且还降低了生产成本。
综上所述,本发明提供的注射液具有以下有益效果:
1、本发明通过直接补入高分子粘多糖和重组人源胶原蛋白,可快速改善皮肤褶皱、松弛等问题,并且安全性高,无毒副作用。同时在重组人源胶原蛋白混入了局部麻药,减轻了患者治疗初期的痛苦;
2、本发明通过补入多种氨基酸、维生素B、维生素C和PRP凝胶,促进皮肤纤维细胞分泌胶原蛋白,实现了皮肤自我修复。采用纳米微球技术负载氨基酸,防止了在生产和用药过程中氨基酸变质,提高稳定性,并且可在皮内持续释放氨基酸,配合同样具有缓释效果的PRP凝胶,延长治疗效果;
3、本发明通过补入维生素A、维生素C、维生素E和谷胱甘肽,协同作用抑制了自由基降解透明质酸钠,并提供抗衰老的功效。
附图说明
图1是本发明提供的纠正皮肤褶皱注射液的生产工艺流程图;
图2是细胞分泌胶原蛋白含量对比图。
具体实施方式
实施例1
本实施例提供一种纠正皮肤褶皱的注射液及其生产工艺,配方:
交联透明质酸钠3.36g/L、非交联透明质酸钠1.44g/L、硫酸软骨素1.2g/L;脯氨酸210mg/L,甘氨酸210mg/L,丙氨酸210mg/L,亮氨酸35mg/L,异亮氨酸35mg/L;重组人源胶原蛋白400mg/L;维生素A1.2mg/L、维生素B4.8mg/L、维生素C4.8mg/L、维生素E1.2mg/L;盐酸利多卡因0.5mg/L;葡萄籽提取物0.3g/L、谷胱甘肽1.2g/L;PRP凝胶10mg/L。
按上述配方制备样品,具体包括以下步骤:
1)取新鲜静脉血液20ml,加入25mgACD-A(抗凝剂,由上海远慕生物公司提供),严格均分至两个15ml离心管,低温(3℃)冷冻离心15min(离心力150×g),保留上层血浆,再将血浆离心25min(离心力250×g),保留下层血小板和下部2ml血浆,振荡混匀,得到A液;
2)取5mg氯化钙经纳米分散机处理10min后,加入A液,置于37℃恒温水浴条件下反应24h,得到PRP凝胶;
3)称取400mg重组人源胶原蛋白,在37℃恒温水浴的条件下,溶解于50ml生理盐水中,溶解完全后,加入10mgPRP凝胶,充分搅拌,得到a液;
4)称取交联透明质酸钠3.36g、非交联透明质酸钠1.44g、硫酸软骨素1.2g、葡萄籽提取物0.3g、谷胱甘肽1.2g、盐酸利多卡因0.5mg、维生素A1.2mg、维生素B4.8mg、维生素C4.8mg、维生素E1.2mg,在60℃恒温水浴的条件下,溶于300ml注射用水,充分搅拌混合均匀,冷却至36.5℃,得到溶液b;
5)称取脯氨酸210mg,甘氨酸210mg,丙氨酸210mg,亮氨酸35mg,异亮氨酸35mg,干混均匀后溶于50ml注射用水中,混合均匀;将酯化果胶溶于常温缓冲溶液中,加入配好的氨基酸溶液,在30℃恒温水浴静置反应3h,再回流反应2h,用100ml注射用水作透析液,透析2h后真空干燥袋内物质,得到氨基酸-果胶纳米微球;袋外溶液全部留存,记为c液;
5)在36℃恒温条件下,将a液、c液和d液充分混匀,采用低功率均质机进一步处理,静置24h,得到d液;
6)将氨基酸-果胶纳米微球加入d液,充分混合后通过0.5mol/L的盐酸调整pH至7.0-7.2,定容至1L,完成后用蠕动泵罐装至西林瓶或者安瓿瓶中,进行高压蒸汽灭菌2min,得到产品。
实施例2
本实施例提供一种纠正皮肤褶皱的注射液,配方:
交联透明质酸钠1.12g/L、非交联透明质酸钠0.48g/L、硫酸软骨素0.4g/L;脯氨酸210mg/L,甘氨酸210mg/L,丙氨酸210mg/L,亮氨酸35mg/L,异亮氨酸35mg/L;重组人源胶原蛋白400mg/L;维生素A1.2mg/L、维生素B4.8mg/L、维生素C4.8mg/L、维生素E1.2mg/L;盐酸利多卡因0.5mg/L;葡萄籽提取物0.3g/L、谷胱甘肽1.2g/L;PRP凝胶10mg/L。
本实施例中注射液的生产工艺与实施例1相同。
实施例3
本实施例提供一种纠正皮肤褶皱的注射液,配方:
交联透明质酸钠4.48g/L、非交联透明质酸钠1.92g/L、硫酸软骨素1.6g/L;脯氨酸210mg/L,甘氨酸210mg/L,丙氨酸210mg/L,亮氨酸35mg/L,异亮氨酸35mg/L;重组人源胶原蛋白400mg/L;维生素A1.2mg/L、维生素B4.8mg/L、维生素C4.8mg/L、维生素E1.2mg/L;盐酸利多卡因0.5mg/L;葡萄籽提取物0.3g/L、谷胱甘肽1.2g/L;PRP凝胶10mg/L。
本实施例中注射液的生产工艺与实施例1相同。
实施例4
本实施例提供一种纠正皮肤褶皱的注射液,配方:
交联透明质酸钠1.2g/L、非交联透明质酸钠4.8g/L;脯氨酸210mg/L,甘氨酸210mg/L,丙氨酸210mg/L,亮氨酸35mg/L,异亮氨酸35mg/L;重组人源胶原蛋白400mg/L;维生素A1.2mg/L、维生素B4.8mg/L、维生素C4.8mg/L、维生素E1.2mg/L;盐酸利多卡因0.5mg/L;葡萄籽提取物0.3g/L、谷胱甘肽1.2g/L;PRP凝胶10mg/L。
本实施例中注射液的生产工艺与实施例1相同。
对比例1
本对比例提供一种纠正皮肤褶皱的注射液,配方:
交联透明质酸钠1.2g/L、非交联透明质酸钠4.8g/L、硫酸软骨素1g/L;脯氨酸210mg/L,甘氨酸210mg/L,丙氨酸210mg/L,亮氨酸35mg/L,异亮氨酸35mg/L;重组人源胶原蛋白400mg/L;维生素A1.2mg/L、维生素B4.8mg/L、维生素C4.8mg/L、维生素E1.2mg/L;盐酸利多卡因0.5mg/L;葡萄籽提取物0.3g/L、谷胱甘肽1.2g/L;PRP凝胶10mg/L。
本对比例中注射液的生产工艺与实施例1相同。
对比例2
交联透明质酸钠6g/L;脯氨酸210mg/L,甘氨酸210mg/L,丙氨酸210mg/L,亮氨酸35mg/L,异亮氨酸35mg/L;重组人源胶原蛋白400mg/L;维生素A1.2mg/L、维生素B4.8mg/L、维生素C4.8mg/L、维生素E1.2mg/L;盐酸利多卡因0.5mg/L;葡萄籽提取物0.3g/L、谷胱甘肽1.2g/L,PRP凝胶10mg/L。
本对比例中注射液的生产工艺与实施例1相同。
实施例5
在本实施例中,注射液成分含量和生产工艺同实施例1,局部麻药选用丁卡因。
实施例6
在本实施例中,注射液成分含量和生产工艺同实施例1,抗氧化物选用L-肌肽。
对比例3
在本对比例中,注射液成分含量与实施例1相同,其中,制备过程中氨基酸不采用纳米微球技术处理,直接将氨基酸溶解后与a液和b液混合。
对比例4
在本对比例中,不加入抗氧化剂,其余组分和生产工艺同实施例1。
对比例5
在本对比例中,不加入维生素B和维生素C,其余组分和生产工艺同实施例1。
(1)剪切粘度评价
对实施例1-4和对比例1-2的样品注射液进行剪切粘度测定,测试条件:在常温环境下,采用TRILOS旋转流变仪在剪切速率从0.001 S-1~1000 S-1进行蠕动扫描,记录在剪切速率为200 S-1下的值作为样品的剪切粘度。实验结果如表1所示。
表1 各样品的剪切粘度
由表1测定结果可知,增大高分子粘多糖含量,注射液粘度上升;增加非交联透明质酸钠的含量,注射液粘度大幅下降,因此可通过调控非交联透明质酸钠的占比,针对性生产作用于不同部位皮肤的注射液;相比于采用纯交联透明质酸钠制备的注射液,本发明提供的实施例1-4的注射液样品,粘度更低,有利于进行皮内注射;硫酸软骨素可增加透明质酸钠的粘度,实施例4和对比例1的结果证实了这一结论,因此本发明提供的注射液注入皮肤后,在透明质酸钠和硫酸软骨素协同作用下,使得皮肤更具弹性。
(2)生物安全性和药效持续性评价
对实施例1-6和对比例3-4的注射液样品进行小鼠活体实验,随机选取同一环境,同一批培育的200天龄的小鼠18只,雌雄各半,每份注射液样品注射2只小鼠作为一组平行样,选2只小鼠注入等量生理盐水,作为对照。正常饲养,定时观察小鼠状态和注射处有无异常,并作等级评价。观察结果共分为4个等级:1级为进食正常,状态良好,注射处无异常;2级为进食正常,状态良好,注射处有不良反应;3级为食欲减退,精神萎靡,注射处有不良反应;4级为死亡。若观察发现小鼠有异常情况,不做处理,继续饲养。结果见表2。
表2 小鼠活体实验安全性评价结果
由表2结果可以发现,各实施例的注射液样品安全性高,无毒副作用,并且出现红肿等异常情况的概率极低,并且不作任何处理,短时间即可恢复正常。
将1#、11#、12#、15#、16#小鼠继续饲养,饲养条件为:每天增加4h紫外线定点照射注射处,其余不变。44d后观察注射处皮肤状态。结果发现,1#小鼠注射处肤色略深于周围;11#和12#小鼠注射处肤色与周围差异明显;15#和16#小鼠注射处皮肤呈黑红色,并轻微蜕皮。说明,在注射液中添加抗氧化剂能够有效提高皮肤的光老化抗性,葡萄籽提取物和谷胱甘肽复配使用,效果较好。
将2#、13#、14#、17#、18#小鼠继续饲养,饲养条件不变。120d后处死小鼠,取下注射处皮肤去掉脂肪后,采用胶原蛋白ELISA测试剂盒测试胶原蛋白含量,结果如表3所示。
表3 120d后小鼠注射处皮肤胶原蛋白含量
由表3结果可知,小鼠接种本发明提供的注射液后,能在较长时间后,仍然促进皮肤细胞合成胶原蛋白,使得胶原蛋白含量保持较高水平,尤其对氨基酸采用纳米微球技术处理后,其作用更为稳定,因此该注射液能够持续性的对皮肤进行修复。
(3)细胞分泌胶原蛋白含量评价
选取实施例1-3、对比例3和对比例5的注射液样品进行细胞培养,7d和60d后采用胶原蛋白ELISA测试剂盒测试总胶原蛋白含量,结果如图2所示。结果显示,高分子粘多糖对胶原蛋白的分泌有促进作用;氨基酸不作纳米微球技术处理,前期对胶原蛋白分泌促进更明显,处理后促进效果持续时间更长;维生素B和维生素C是促进胶原蛋白内源分泌必不可少的辅助因子。
本具体实施例仅仅是对本发明的解释,其并不是对本发明的限制,本领域技术人员在阅读完本说明书后可以根据需要对本实施例做出没有创造性贡献的修改,但只要在本发明的权利要求范围内都受到专利法的保护。
Claims (10)
1.一种纠正皮肤褶皱的注射液,其特征在于它的质量组成:高分子粘多糖2~8g/L;氨基酸400~800mg/L;重组人源胶原蛋白50~500mg/L;维生素1~20mg/L;局部麻药0.2~0.8mg/L;抗氧化剂0.5~2g/L;PRP凝胶1~20mg/L。
2.按照权利要求1所述的注射液,其特征在于所述的高分子粘多糖为透明质酸钠和硫酸软骨素,质量比为8:2,其中透明质酸钠交联与非交联形式的质量比为7:3。
3.按照权利要求1所述的注射液,其特征在于所述氨基酸包括脯氨酸,甘氨酸,丙氨酸,亮氨酸,异亮氨酸,质量比为3:3:3:0.5:0.5。
4.按照权利要求1所述的注射液,其特征在于所述维生素包括维生素A,维生素B,维生素C和维生素E,质量比为1:4:4:1。
5.按照权利要求1所述的注射液,其特征在于所述局部麻药为盐酸利多卡因或丁卡因;优选的,所述局部麻药为盐酸利多卡因。
6.按照权利要求1所述的注射液,其特征在于所述抗氧化剂为葡萄籽提取物,L-肌肽,谷胱甘肽中的一种或多种;优选的,所述抗氧化剂为葡萄籽提取物和谷胱甘肽混合物,质量比为1:4。
7.按照权利要求1所述的注射液,其特征在于它的质量组成:高分子粘多糖6~8g/L;氨基酸400~800mg/L;重组人源胶原蛋白50~500mg/L;维生素1~20mg/L;局部麻药0.2~0.8mg/L;抗氧化剂1.8~2g/L;PRP凝胶1~20mg/L;所述高分子粘多糖为透明质酸钠,其交联与非交联形式的质量比为2:8。
8.按照权利要求1所述的注射液,其特征在于它的质量组成:高分子粘多糖6g/L;氨基酸700mg/L;重组人源胶原蛋白400mg/L;维生素12mg/L;局部麻药0.5mg/L;抗氧化剂1.5g/L;PRP凝胶10mg/L。
9.权利要求1-8任一项所述的注射液的生产工艺,其特征在于包括以下步骤:
S1,PRP凝胶制备:
S11,取新鲜静脉血液,加入ACD-A,低温(1~3℃)冷冻离心10~15min(离心力150×g),保留上层血浆,再将血浆离心25min(离心力250×g),保留下层血小板和少量血浆,振荡混匀,得到A液;
S12,取氯化钙经纳米分散机处理后,加入A液,置于36~37℃恒温水浴条件下反应24h,得到PRP凝胶;
S2,注射液制备
S21,36~37℃恒温水浴的条件下,将重组人源胶原蛋白溶解于生理盐水中,加入PRP凝胶,充分混合后加入注射用水,充分搅拌,得到a液;
S22,55~60℃恒温水浴的条件下,将高分子粘多糖、抗氧化剂、局部麻药和维生素按比例溶于注射水,混合均匀,冷却至36.5℃,得到溶液b;
S23,将酯化果胶溶于常温缓冲溶液中,加入氨基酸溶液,30~35℃恒温水浴反应2~4h,再回流反应1~2h,用透析袋透析后真空干燥袋内物质,得到氨基酸-果胶纳米微球,袋外溶液全部留存,记为c液;
S24,在36~37℃恒温条件下,将a液、b液和c液充分混匀,采用低功率均质机进一步处理,静置24~28h,得到d液;
S25,将氨基酸-果胶纳米微球加入d液,充分混合后通过0.5mol/L的盐酸调整pH至7.0~7.2,完成后用蠕动泵罐装至西林瓶或者安瓿瓶中,进行高压蒸汽灭菌,得到产品。
10.按照权利要求9所述的注射液生产工艺,其特征在于所述缓冲溶液为甘氨酸-柠檬酸缓冲溶液,pH=4.5;所述酯化果胶De=70%;所述纳米微球粒径为50~200nm。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210296734.3A CN114522223A (zh) | 2022-03-24 | 2022-03-24 | 一种纠正皮肤褶皱的注射液及其生产工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210296734.3A CN114522223A (zh) | 2022-03-24 | 2022-03-24 | 一种纠正皮肤褶皱的注射液及其生产工艺 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114522223A true CN114522223A (zh) | 2022-05-24 |
Family
ID=81626761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210296734.3A Pending CN114522223A (zh) | 2022-03-24 | 2022-03-24 | 一种纠正皮肤褶皱的注射液及其生产工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114522223A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114848527A (zh) * | 2022-06-02 | 2022-08-05 | 浙江珂瑞康生物医疗科技有限公司 | 一种注射用胶原复合溶液及其制备方法 |
CN114903829A (zh) * | 2022-05-25 | 2022-08-16 | 浙江天妍生物科技有限公司 | 一种美容注射液的制备方法及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104189952A (zh) * | 2014-08-05 | 2014-12-10 | 北京爱美客生物科技有限公司 | 纠正皮肤褶皱注射液及其制备方法 |
US20200164037A1 (en) * | 2018-11-27 | 2020-05-28 | Labo Cosprophar Ag | Dermocosmetic composition containing synthetic platelet-like molecules to treat skin aging and stimulate hair growth |
CN111467568A (zh) * | 2019-01-23 | 2020-07-31 | 爱美客技术发展股份有限公司 | 一种交联透明质酸钠复合溶液制剂及其制备方法和应用 |
CN113521258A (zh) * | 2021-08-03 | 2021-10-22 | 北京美神煦氰美啦医疗美容诊所有限公司 | 一种改善衰老的组织注射液 |
CN113975246A (zh) * | 2021-11-23 | 2022-01-28 | 郑州大学第一附属医院 | 一种注射用多烯紫杉醇及其制备方法 |
-
2022
- 2022-03-24 CN CN202210296734.3A patent/CN114522223A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104189952A (zh) * | 2014-08-05 | 2014-12-10 | 北京爱美客生物科技有限公司 | 纠正皮肤褶皱注射液及其制备方法 |
US20200164037A1 (en) * | 2018-11-27 | 2020-05-28 | Labo Cosprophar Ag | Dermocosmetic composition containing synthetic platelet-like molecules to treat skin aging and stimulate hair growth |
CN111467568A (zh) * | 2019-01-23 | 2020-07-31 | 爱美客技术发展股份有限公司 | 一种交联透明质酸钠复合溶液制剂及其制备方法和应用 |
CN113521258A (zh) * | 2021-08-03 | 2021-10-22 | 北京美神煦氰美啦医疗美容诊所有限公司 | 一种改善衰老的组织注射液 |
CN113975246A (zh) * | 2021-11-23 | 2022-01-28 | 郑州大学第一附属医院 | 一种注射用多烯紫杉醇及其制备方法 |
Non-Patent Citations (2)
Title |
---|
TOMMASO IANNITTI 等: ""Experimental and Clinical Efficacy of Two Hyaluronic Ac id-based Compounds of Different Cross-Linkage and Composition in the Rejuvenation of the Skin"", 《PHARM RES》, vol. 33, pages 2879 - 2890, XP036089060, DOI: 10.1007/s11095-014-1354-y * |
刘悦 等: ""肉毒素联合药物在我国整形美容方面应用进展"", 《化工时刊》, vol. 35, no. 4, pages 32 - 35 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114903829A (zh) * | 2022-05-25 | 2022-08-16 | 浙江天妍生物科技有限公司 | 一种美容注射液的制备方法及其应用 |
CN114848527A (zh) * | 2022-06-02 | 2022-08-05 | 浙江珂瑞康生物医疗科技有限公司 | 一种注射用胶原复合溶液及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114522223A (zh) | 一种纠正皮肤褶皱的注射液及其生产工艺 | |
KR102256061B1 (ko) | 하이알루론산의 가교 방법, 주사용 하이드로젤의 제조방법, 수득한 하이드로젤 및 수득한 하이드로젤의 용도 | |
RU2648450C2 (ru) | Приемлемая для инъекций стерильная водная композиция на основе сшитой гиалуроновой кислоты и гидроксиапатита для применения в пластической хирургии | |
EP3566713B1 (en) | Injectable biomaterials | |
CN112294668B (zh) | 透明质酸注射液 | |
CN109432123B (zh) | 一种复方电解质葡萄糖注射液及其制备方法 | |
Marktl et al. | The effect of factor XIII on wound granulation in the rat | |
Wang et al. | Natural small molecule-induced polymer hydrogels with inherent antioxidative ability and conductivity for neurogenesis and functional recovery after spinal cord injury | |
CN115192771B (zh) | 一种含透明质酸-多聚脱氧核糖核苷酸共聚物的凝胶及其用途 | |
CN114133465B (zh) | 一种透明质酸钾的制备方法及所得产品和应用 | |
CN117357634A (zh) | 一种蛋白注射液及其制备方法 | |
CN102145164B (zh) | 一种更加稳定的iapp类似物注射剂 | |
CN106692179A (zh) | 关节腔注射用含低分子量黄原胶的药物制剂及其制备方法 | |
AU2002327105B2 (en) | Separate type medical material | |
US20090023631A1 (en) | Composition and Method of Use for Soft Tissue Augmentation/Drug Delivery | |
CN110665060A (zh) | 一种骨修复材料及其制备方法和应用 | |
CN118058993A (zh) | 注射用复合营养溶液及其制备方法 | |
CN111000974B (zh) | 一种兔奶活性小肽溶液及其提取方法和应用 | |
CN113786388B (zh) | 一种白及多糖改良那他霉素的方法及应用 | |
RU2811867C1 (ru) | Фармацевтическая композиция стерильной эмульсии перфторорганических соединений и полиэлектролитов и способ ее получения | |
CN110787287B (zh) | 一种鱼鳞胶原蛋白多肽在制备治疗慢性心力衰竭药物中的应用 | |
CN114712481B (zh) | 一种复合植物源多肽及其制备方法与应用 | |
CN100386113C (zh) | 脑蛋白水解物注射剂及其制备工艺 | |
CN112245387B (zh) | 一种重酒石酸间羟胺注射液的组成及制备方法 | |
KR102348467B1 (ko) | Dna 분획물을 포함하는 필러 제조방법 및 이로부터 제조된 필러 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |